Clinical Trials Logo

Tricuspid Valve Insufficiency clinical trials

View clinical trials related to Tricuspid Valve Insufficiency.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06033274 Enrolling by invitation - Clinical trials for Tricuspid Regurgitation

Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment

TRIPLACE
Start date: October 5, 2023
Phase:
Study type: Observational

The field of transcatheter tricuspid valve replacement (TTVR) is rapidly emerging and data on this topic are scarce. Particularly, little is known about which patients are at greatest risk of procedural complications, such as the timing and onset of conduction disturbances necessitating permanent pacemaker implantation, and how such patients are managed. On this background, the TRIPLACE Registry - an investigator-initiated global multicenter registry - is aimed at better understanding the safety and efficacy of orthotopic TTVR.

NCT ID: NCT05825898 Enrolling by invitation - Clinical trials for Tricuspid Regurgitation

Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment

TRIGISTRY
Start date: September 1, 2022
Phase:
Study type: Observational

Tricuspid regurgitation (TR) is a public health problem: moderate / severe TR are common, especially in ageing populations, and affect 4% of the population >75 years old, totaling approximately 1.6 million in the US and 3 million in Europe. TR is associated with an increased risk of mortality and morbidity. Contrasting with TR prevalence and the magnitude of the problem, the vast majority of patients are medically treated with diuretics to relieve their symptoms and a curative surgical treatment for isolated severe TR is seldom performed. Reluctance to perform an ITVS can be explained in the one hand by the limited evidence that TR correction improves outcomes and on the other hand, ITVS is associated to high observed in-hospital mortality rates (≈ 10% remarkably consistent in most series across the literature). Severity of the clinical presentation is the main predictor of outcome after surgery. The TRI-SCORE, is a dedicated, simple and accurate risk score model to predict in-hospital mortality after ITVS that could guide the clinical decision-making process at the individual level. Excellent outcomes can be achieved when patients present with low TRI-SCORE. These results suggest adopting a more pro-active approach for TV interventions, and to intervene earlier in the course of the disease in patients with severe isolated TR, irrespective of TR mechanism / etiology, before the occurrence of advanced / irreversible consequences such as severe RV dilatation / dysfunction, renal and liver failure, and intractable heart failure. Recently transcatheter tricuspid valve interventions (TTVI) have emerged recently as a less invasive option to surgery to cure patients with TR. What is the best treatment between medical, surgical or transcatheter therapy to consider and the best timing for each patient are not clearly defined. The aim of the study is to compare outcome of patients with significant functional TR according to medical, transcatheter or surgical treatment after matching per TRISCORE.

NCT ID: NCT05628779 Enrolling by invitation - Clinical trials for Cardiac Catheterization

Evaluating Edge-to-edge Transcatheter Tricuspid Valve Repair in Patients With Severe Symptomatic Tricuspid Regurgitation

TRACE-NL
Start date: December 12, 2022
Phase: N/A
Study type: Interventional

This is a national multicenter, open-label, randomized controlled trial to show superiority of edge-to-edge Transcatheter Tricuspid Valve repair (TTVr) on top of the Standard Of Care (SOC; heart failure medication) over the SOC alone in patients with symptomatic severe Tricuspid Regurgitation (TR) in the Netherlands.

NCT ID: NCT04921605 Enrolling by invitation - Clinical trials for Tricuspid Regurgitation

Feasibility Study of Dragonfly System for Severe Tricuspid Regurgitation

Start date: December 15, 2020
Phase: N/A
Study type: Interventional

The study is designed to assess the feasibility of the DragonFly transcatheter mitral valve clamping system for the treatment of symptomatic severe tricuspid regurgitation.